Large-scale research data, including pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials, and a nationwide Danish registry-based cohort in over 120,000 patients, suggests GLP-1s reduce the incidence of dementia, especially in patients with type 2 diabetes [19]
Semaglutide injections come in solution form and theres a greater risk of contamination, bacterial, or fungal growth in the solution when using the medication beyond its shelf life
Yes, plateau is common as your body adapts to GLP-1 receptor signaling
Wegovy GLP-1 receptor agonist only Average weight loss of approximately 1315% in clinical trials In head-to-head comparison, semaglutide achieved 13.7% mean weight loss at 72 weeks Often better tolerated for some individuals Zepbound Dual GIP and GLP-1 receptor agonist Average weight loss of 1521% , depending on dose 5 mg: ~15% 10 mg: ~19.5% 15 mg: ~21% In head-to-head comparison, tirzepatide achieved 20.2% mean weight loss at 72 weeks This does not mean Zepbound is universally superior
Gofton C, Upendran Y, Zheng MH, George J
Two options that often come up are Ozempic (semaglutide) and compounded semaglutide